Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Am Heart J ; 116(1 Pt 1): 85-90, 1988 Jul.
Article in English | MEDLINE | ID: mdl-3164977

ABSTRACT

Eight type III hyperlipoproteinemic (type III HLP), homozygous E 2/2 patients were enrolled in two periods of long-term diet-gemfibrozil treatment. The combined therapy resulted in highly significant decreases in their low-density lipoprotein cholesterol, very-low density lipoprotein cholesterol, very-low density lipoprotein triglycerides, and increases in their high-density lipoprotein cholesterol during the first treatment period of 24 to 28 months. Type III HLP reasserted itself following an 8-week interruption of gemfibrozil therapy. Resumption of gemfibrozil therapy again lowered the high lipid-lipoprotein concentrations of these patients toward normal. Tuboeruptive xanthomata, palmar xanthoma, and xanthoma striata palmare subsided with treatment. Follow-up coronary arteriograms performed 2.5 to 3.0 years after initiation of diet-drug treatment showed stabilization of coronary arterial lesions, which was associated with improvement in exercise tolerance.


Subject(s)
Coronary Disease/prevention & control , Hyperlipoproteinemia Type III/drug therapy , Hypolipidemic Agents/therapeutic use , Pentanoic Acids/therapeutic use , Valerates/therapeutic use , Adult , Combined Modality Therapy , Coronary Disease/etiology , Drug Evaluation , Exercise Test , Female , Gemfibrozil , Hand Dermatoses/etiology , Hand Dermatoses/prevention & control , Humans , Hyperlipoproteinemia Type III/complications , Hyperlipoproteinemia Type III/diet therapy , Hypolipidemic Agents/adverse effects , Lipids/blood , Lipoproteins/blood , Male , Middle Aged , Pentanoic Acids/adverse effects , Xanthomatosis/etiology , Xanthomatosis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...